Navigation Links
Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
Date:5/9/2011

ledge and recognition in the diagnostics industry, we are confident we will successfully commercialize Saladax's assays in China and Australia," said Edward L. Erickson, president and CEO of Saladax.  

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
VP Marketing & Sales
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Farrell Denby
fdenby@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
3. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
4. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... SANTA BARBARA, Calif., Dec. 6, 2010 Direct ... has donated critically needed medical supplies to assist cholera ... University Hospital (JUH) in Cap-Haitien. JUH is the main public ... I.V. solutions and supplies will also be distributed to the ...
... DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, ... of their first-in-class CK2 inhibitor at the 52nd Annual Meeting ... on December 4-7 in Orlando, FL, the company announced today. ... on targeting CK2, a protein kinase that is essential for ...
Cached Medicine Technology:CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 2CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti 3Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 2Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting 3
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... Las Vegas, NV (PRWEB) August 01, 2014 ... issues and opportunities for independent community pharmacies. At ... tradeshow, pharmacists are equipped with practices and resources ... General Session, AmerisourceBergen leaders focused on critical issues ... to learn, optimize and grow. , ThoughtSpot ...
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... 9, 2010) An ultra-low-molecular-weight heparin called semuloparin ... venous thromboembolism in orthopedic surgery patients in a ... committee chaired by McMaster University professor Dr. Alexander ... completed international clinical studies on short-term venous thromboembolism ...
... ... ... bliss is not all it’s cracked up to be. Oh, sure, it’s great while it ... of July sparkler. , , ,Long-lasting, transformational marriages rely on more than passion to thrive, ...
... ... Khoi Nguyen and Dennis McDowell have joined their executive sales staff in the Houston ... the area,s most influential hospitals and providers. Accel is the Company’s top tier network ... providers. , ...
... BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the ... of a number of hemophilia studies will be presented ... taking place July 10-14, 2010, in Buenos Aires, Argentina. ... Xa as a potential new approach to restoring hemostasis, ...
... ... nation to receive the “Best Practice” award from Safety Net Solutions. The award recognizes the ... for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s Dental Clinic is one ...
... ... health problems, Sam’s Club is hosting free health screenings in more than 400 of its ... ... To help its members and community residents detect a range of preventable health problems, Sam’s ...
Cached Medicine News:Health News:Drug study shows improvement in major orthopedic surgery care 2Health News:When the Fireworks Fizzle: How to Stoke the Flames of Lasting Love 2Health News:HealthSmart Adds Experienced Professionals to Houston Sales Force 2Health News:Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress 2Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:Sam's Club Hosts Health Screenings July 10 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: